EMA Authorised: Aquipta (atogepant) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

The European Medicines Agency authorised Aquipta (atogepant) by AbbVie Deutschland GmbH & Co. KG for migraine disorders, marking EU regulatory approval for the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine Disorders

Drugs mentioned

• Aquipta (atogepant)

Snippet

Status: Authorised. Therapeutic area: Migraine Disorders. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 08/05/2025